Study Finds No Difference in Disease-free, Overall Survival for HER2+ Breast Cancer Patients Receiving Treatment Concurrently or Sequentially
September 06, 2018
September 06, 2018
HOUSTON, Texas, Sept. 6 -- The University of Texas MD Anderson Cancer Center issued the following news release:
New research in women with HER2+ breast cancer found no difference in disease-free survival (DFS) and overall survival (OS) when receiving anthracycline-based chemotherapy and trastuzumab concurrently or sequentially in the neoadjuvant setting. Findings from The University of Texas MD Anderson Cancer Center-led study published today in JAMA Oncology.
The Phase . . .
New research in women with HER2+ breast cancer found no difference in disease-free survival (DFS) and overall survival (OS) when receiving anthracycline-based chemotherapy and trastuzumab concurrently or sequentially in the neoadjuvant setting. Findings from The University of Texas MD Anderson Cancer Center-led study published today in JAMA Oncology.
The Phase . . .